<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722108</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0110/1807</org_study_id>
    <secondary_id>2018-002374-46</secondary_id>
    <nct_id>NCT03722108</nct_id>
  </id_info>
  <brief_title>Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas</brief_title>
  <acronym>REGIRI</acronym>
  <official_title>A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan
      alone in second-line treatment of patients with metastatic gastro-oesophageal
      adenocarcinomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative interventional prospective phase 2, randomised, open-label, multicentric trial
      comparing the combination of regorafenib and irinotecan (REGIRI) to irinotecan alone (IRI) as
      second line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of overall survival (OS)</measure>
    <time_frame>expected duration of 10 months from randomisation</time_frame>
    <description>Time duration from randomisation to time of death of any cause. If a patient is alive at the database cut-off date, then the patient will be censored at the last date of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the overall survival rate</measure>
    <time_frame>6 and 12 months from randomisation</time_frame>
    <description>Overall survival rates at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the progression-free survival (PFS)</measure>
    <time_frame>expected duration of 6 months from randomisation</time_frame>
    <description>Time duration from randomisation to time of first event (locoregional or distant relapse or progression, second malignancy, death from any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the progression-free survival rate</measure>
    <time_frame>6 and 12 months from randomisation</time_frame>
    <description>Progression-free survival rates at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the disease control rate (DCR)</measure>
    <time_frame>expected duration of 6 months from randomisation</time_frame>
    <description>Percentage of patients with complete response, partial response or stable disease as best response at the database cut-off date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of regorafenib combined with irinotecan versus irinotecan alone in terms of the objective response rate (ORR)</measure>
    <time_frame>expected duration of 6 months from randomisation</time_frame>
    <description>Percentage of patients with complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare treatment-related toxicity</measure>
    <time_frame>expected 30 days after last study treatment administration</time_frame>
    <description>Frequency and severity of adverse events assessed by NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the effect of treatment on quality of life</measure>
    <time_frame>expected 30 days after last study treatment administration</time_frame>
    <description>Evaluation of quality of life with EORTC quality of life questionnaire for cancer patients (QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the effect of treatment on quality of life related to gastro-oesophageal cancer</measure>
    <time_frame>expected 30 days after last study treatment administration</time_frame>
    <description>Evaluation of quality of life with EORTC quality of life specific questionnaire for gastro-oesophageal tumours (QLQ-OG25)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Adenocarcinoma of the Stomach</condition>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <arm_group>
    <arm_group_label>Regorafenib and Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Regorafenib and Irinotecan</intervention_name>
    <description>Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity</description>
    <arm_group_label>Regorafenib and Irinotecan</arm_group_label>
    <other_name>STIVARGA</other_name>
    <other_name>CAMPTO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity</description>
    <arm_group_label>Irinotecan</arm_group_label>
    <other_name>CAMPTO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must have signed a written informed consent form prior to any study specific
             procedures

          2. Patients aged ≥18 years old

          3. Histologically confirmed diagnosis of gastro-oesophageal adenocarcinomas:
             gastroesophageal junction (Siewert II and III) and gastric adenocarcinomas

          4. Asymptomatic primary tumour

          5. Metastatic disease

          6. At least one target lesion (according to RECIST v1.1):

               -  Unidimensionally measurable on cross-sectional imaging

               -  In an area not previously irradiated

          7. Disease progression after a fluoropyrimidine and platinum agent-based chemotherapy
             (5-fluorouracil or 5-fluorouracil prodrugs combined with cisplatin or oxaliplatin).
             For example, docetaxel combined with FOLFOX, PD-L1/PD-1 inhibitors combined with
             FOLFOX, LV5-FU2-cisplatin or 5-fluorouracil-cisplatin are acceptable prior therapies.

          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          9. Life expectancy &gt;3 months

         10. Amylase ≤1.5 x upper limit of normal (ULN) and lipase ≤1.5 x ULN

         11. Adequate liver function:

               -  Total bilirubin ≤1.5 x ULN

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN
                  (≤5 x ULN for patients with liver metastasis)

               -  Alkaline phosphatase (ALP) ≤2.5 x ULN (≤5.0 x ULN for patients with liver or bone
                  metastases)

         12. Platelet count ≥100,000/mm³; haemoglobin (Hb) ≥9 g/dL; absolute neutrophil count (ANC)
             ≥1,500/mm³. The use of blood transfusion(s) to meet the inclusion criteria will not be
             allowed

         13. International normalised ratio (INR) ≤1.5 x ULN and partial thromboplastin time (PTT)
             or activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless receiving treatment
             with therapeutic anticoagulation. Patients being treated with anticoagulant, e.g.,
             heparin, are eligible if there is no evidence of an underlying abnormality with these
             parameters and if a close monitoring of at least weekly evaluations was performed
             until INR and PTT are stable based on a pre-dose measurement as defined by the local
             standard of care

         14. Creatinine clearance (CLcr) ≥50 mL/min estimated by Cockcroft-Gault equation

         15. Women of childbearing potential and men must agree to use adequate contraception
             during the study and for at least 3 months after the last study drug administration

         16. Patients affiliated to the social security system

        Exclusion Criteria:

          1. Symptomatic brain metastases or carcinomatous meningitis

          2. Bone-only metastasis

          3. Known and documented UGT1A1 deficiency

          4. History of Gilbert's syndrome

          5. Previous or concurrent cancer with a distinct primary site, other than
             gastro-oesophageal cancer, within 5 years prior to randomisation (except for
             curatively treated cervical cancer in situ, non-melanoma skin cancer, and superficial
             bladder tumours)

          6. Persistent proteinuria &gt;3.5 g/24 h measured by urine protein-creatinine ratio from a
             random urine sample (grade ≥3, NCI-CTCAE v 5.0)

          7. Interstitial lung disease with ongoing signs and symptoms at inclusion

          8. Known hypersensitivity to any of the study drugs, study drug classes, or excipients

          9. Non-healing wound, non-healing ulcer, or non-healing bone fracture

         10. Patients with evidence or history of any bleeding diathesis, irrespective of severity

         11. Any haemorrhage or bleeding event grade ≥3 (NCI-CTCAE v.5.0) within 4 weeks before
             starting of the study treatment

         12. Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 6 month before starting the study treatment (except for adequately treated
             catheter-related venous thrombosis occurring more than one month before the start of
             study medication)

         13. Previous major surgical procedure, significant traumatic injury, or radiotherapy
             within the 4 weeks before inclusion

         14. Uncontrolled hypertension (systolic blood pressure &gt;140 mmHg or diastolic pressure &gt;90
             mmHg) despite optimal medical management. Congestive heart failure: New York Heart
             Association (NYHA) ≥ class 2

         15. Unstable angina (angina symptoms at rest), new-onset angina (that started within the
             last 3 months)

         16. Myocardial infarction less than 6 months before starting the study treatment

         17. Uncontrolled cardiac arrhythmias

         18. History of epileptic seizures requiring long-term anticonvulsant therapy

         19. History of organ transplantation with use of immunosuppression therapy

         20. Ongoing bacterial or fungal infection (grade &gt;2 by NCI-CTCAE v.5.0)

         21. Known history of human immunodeficiency virus (HIV) infection

         22. Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with
             antiviral therapy

         23. Use of CYP3A4 inducers or inhibitors

         24. Pregnant or breast-feeding women

         25. Bowel malabsorption or extended bowel resection that could affect the absorption of
             regorafenib, occlusive syndrome, inability to take oral medications

         26. Inflammatory bowel disease with chronic diarrhoea

         27. Participation in another clinical trial within the 30 days before inclusion

         28. Concurrent treatment with another investigational product or anticancer therapy (other
             than irinotecan or regorafenib)

         29. Concomitant treatment with hypericum or live attenuated vaccines

         30. Gastro-intestinal fistula or perforation

         31. Person kept in detention or incapable of giving consent

         32. Patient unwilling or unable to comply with the medical follow-up required by the study
             because of geographic, social, or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle SAMALIN-SCALZI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure MONARD</last_name>
    <phone>33 (0)173797309</phone>
    <email>l-monard@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest-Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène SENELLART</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe METGES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey HENNEQUIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez - CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony TURPIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christelle DE LA FOUCHARDIERE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laëtitia DAHAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine GILABERT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle SAMALIN-SCALZI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludovic EVESQUE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aziz ZAANAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza KHEMISSA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David TOUGERON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien BOTSEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David SEFRIOUI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest-René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène SENELLART</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strass</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meher BEN ABDELGHANI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony LOPEZ</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>gastro-oesophageal</keyword>
  <keyword>regorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data will not be shared at an individual level, they will be part of the study database including all enrolled patients</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

